Vaxart, Inc. To Present Phase I Data At IDWeek 2015 Demonstrating Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a privately held, clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that Vaxart Associate Director of Immunology Wendy Peters, Ph.D., will present Phase 1 data demonstrating the Vaxart H1N1 influenza tablet vaccine induces dose dependent T cell responses at the upcoming IDWeek 2015 in San Diego.
“An Adenovirus Based Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses”
Dr. Peters will report the data in her poster presentation, “An Adenovirus Based Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses” on Friday, Oct. 9 from 12:30 to 2 p.m. Pacific Daylight Time in Poster Hall at the San Diego Convention Center.
Vaxart is a privately held, clinical-stage company developing a range of tablet vaccines based on its proprietary oral recombinant vaccine platform. Vaxart’s vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer, and eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. Vaxart’s lead programs include tablet vaccines for seasonal influenza, norovirus and Respiratory Syncytial Virus (RSV). For more information, please visit www.vaxart.com.
Katie Hogan, 415-658-9745